Shifting the paradigm of type 1 diabetes: a narrative review of disease modifying therapies

被引:0
作者
O'Donovan, Alexander J. [1 ]
Gorelik, Seth [1 ,2 ]
Nally, Laura M. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA
[2] Bowdoin Coll, Brunswick, ME USA
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词
type; 1; diabetes; stage; 2; 3; teplizumab; disease-modifying therapies; ANTI-CD3; MONOCLONAL-ANTIBODY; C-PEPTIDE RESPONSES; DOUBLE-BLIND; ONSET; TEPLIZUMAB; IDENTIFICATION; PATHOGENESIS; USTEKINUMAB; AUTOANTIGEN; INHIBITOR;
D O I
10.3389/fendo.2024.1477101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A new diagnosis of type 1 diabetes (T1D) may be accompanied by numerous lifelong financial, emotional, and physical challenges, thus advancements in therapies that can delay the onset of clinical disease are crucial. T1D is an autoimmune condition involving destruction of pancreatic beta cells leading to insulin deficiency, hyperglycemia, and long-term insulin dependence. The pathogenesis of T1D is classified into stages, with the first signal being the detection of autoantibodies without any glycemic changes. In the second stage, dysglycemia develops without symptoms, and in stage 3, symptoms of hyperglycemia become apparent, and at this time a clinical diagnosis of T1D is made. As a greater understanding of these stages of T1D have evolved, research efforts have been devoted to delaying the onset of clinical disease. To date, only one medication, teplizumab, has been approved by the Food and Drug Administration (FDA) for the treatment of stage 2 T1D. This narrative review present published trials and ongoing research on disease modifying therapies (DMT) in T1D, the mechanisms of action for each therapy, and the stages of T1D that these interventions are being studied.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes
    Creusot, Remi J.
    Battaglia, Manuela
    Roncarolo, Maria-Grazia
    Fathman, C. Garrison
    STEM CELLS, 2016, 34 (04) : 809 - 819
  • [32] Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation
    Schneider, D. A.
    Kretowicz, A. M.
    von Herrath, M. G.
    DIABETES OBESITY & METABOLISM, 2013, 15 (07) : 581 - 592
  • [33] Therapy concepts in type 1 diabetes mellitus treatment: disease modifying versus curative approaches
    Lenzen, Sigurd
    Joerns, Anne
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2024, 102 (12): : 1451 - 1455
  • [34] C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
    Taylor, Peter N.
    Collins, Kimberly S.
    Lam, Anna
    Karpen, Stephen R.
    Greeno, Brianna
    Walker, Frank
    Lozano, Alejandro
    Atabakhsh, Elnaz
    Ahmed, Simi T.
    Marinac, Marjana
    Latres, Esther
    Senior, Peter A.
    Rigby, Mark
    Gottlieb, Peter A.
    Dayan, Colin M.
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (12) : 915 - 925
  • [35] Combination therapies for Type 1 diabetes: why not now?
    von Herrath, Matthias
    IMMUNOTHERAPY, 2010, 2 (03) : 289 - 291
  • [36] Recent developments in adjunct therapies for type 1 diabetes
    Timmons, Joseph G. G.
    Littlejohn, Lucy
    Boyle, James G. G.
    Petrie, John R. R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, : 1311 - 1320
  • [37] Pharmacological therapies to address obesity in type 1 diabetes
    Casu, Anna
    Bilal, Anika
    Pratley, Richard E.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2020, 27 (04) : 194 - 206
  • [38] Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review
    Gomez-Perez, Ana Maria
    Damas-Fuentes, Miguel
    Cornejo-Pareja, Isabel
    Tinahones, Francisco J.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [39] The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
    Guo, Keyu
    Tian, Qi
    Yang, Lin
    Zhou, Zhiguang
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 4865 - 4873
  • [40] The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
    Burton, Jodie M.
    Freedman, Mark S.
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2018, 38 (02) : 210 - 216